J Neurol Surg B Skull Base 2024; 85(S 01): S1-S398
DOI: 10.1055/s-0044-1780394
Presentation Abstracts
Poster Abstracts

Perioperative Associations between Atorvastatin and Surgically Treated Vestibular Schwannomas: Cranial Nerve Statuses and Neutrophil Lymphocyte Ratio

Authors

  • Bryan Clampitt

    1   USF Health Morsani College of Medicine, Tampa, Florida, United States

  • Mehdi Rizk

    1   USF Health Morsani College of Medicine, Tampa, Florida, United States

  • Maryam Kazelka

    1   USF Health Morsani College of Medicine, Tampa, Florida, United States

  • Alexander Tai

    2   Washington Brain and Spine Institute, Washington, District of Columbia, United States

  • Harry van Loveren

    3   Department of Neurosurgery and Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, Florida, United States

  • Siviero Agazzi

    3   Department of Neurosurgery and Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, Florida, United States

  • Davide Croci

    3   Department of Neurosurgery and Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, Florida, United States
Further Information
Also available at
 

Background and Purpose: Vestibular Schwannomas (VS) represent 6–8% of all intracranial tumors and have recently been implicated to be dependent on inflammatory processes. Atorvastatin is currently one of the most frequently prescribed medications in the United States. It has been shown in the literature that atorvastatin has anti-inflammatory effects. However, there are currently no studies relating atorvastatin to vestibular schwannomas. This study attempts to explore the relationship between atorvastatin and perioperative cranial nerve (CN) outcomes and neutrophil to lymphocyte ratios (NLR) in patients undergoing surgical resection of VS.

Materials and Methods: Retrospective analysis of VS patients operated on between 2013 and 2022 was performed. Measurements of NLR were taken preoperatively and one day postoperatively. CN VIII, VII, and V functions were determined preoperatively and at last follow-up. All patients’ records were reviewed for atorvastatin use prior to their operation.

Results: Analysis included 117 patients (51 males, mean age 51.2 ± 15.2 years). The mean follow-up was 278 days. 13 patients began using atorvastatin with a mean time of 110 days prior to VS resection. Atorvastatin use was not significantly associated with CN VII or CN V deficits nor changes in these deficits, perioperatively or at follow up. Atorvastatin use was minorly associated with higher preoperative Gardner–Robertson hearing class (Pearson vorrelation = 0.309, p < 0.05) and in relative difference in hearing class between the ipsi- and contralateral ears to the VS (Pearson correlation = 0.368, p < 0.05). There was no association between NLR and atorvastatin use in surgically treated VS patients.

Conclusion: Atorvastatin does not appear to be associated with NLR nor the outcomes of CNVII and CNV. In this study, atorvastatin was associated with preoperative hearing loss. However, no conclusion can be drawn from this study. Further studies with higher n are required to better evaluate the role of atorvastatin in CN outcomes in VS.



Publication History

Article published online:
05 February 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany